Stand out for this role — generate a tailored resume and cover letter in about a minute.
AstraZeneca in Boston, MA invites a Director of CVRM Communications focused on obesity to lead global strategies across assets in weight management. You will partner with cross-functional teams and external stakeholders to shape narratives, drive media engagement, and manage crisis readiness in a highly matrixed organisation.
The role demands at least 8 years in pharmaceutical communications, exceptional writing, and the ability to translate science for diverse audiences, with a preference for
Global Corporate Affairs
Hybrid Work- on average 3 days a week from office
This Director, Communications role will be key in developing and executing innovative global communications strategies to support the AstraZeneca's portfolio in Cardiovascular, Renal and Metabolism (CVRM), with a focus on obesity / weight management and metabolism, as the assets and combinations progress through development.
The Communications Director will be a key partner for the cross-functional global franchise teams and global product teams responsible for the clinical development and commercialization of obesity / weight management portfolio, working closely with policy functional leads, key markets and a broad mix of internal stakeholders across BioPharmaceuticals R&D and BBU, CVRM TA, Global Corporate Affairs, Global Medical Affairs, Investor Relations. The role will report to the Head, BioPharma R&D Corporate Affairs with a dotted line into the Head of Global Corporate Affairs, CVRM.
AstraZeneca's weight management and metabolic portfolio is an important growth driver for the Company. Our ambition is to deliver a portfolio of simple, scalable, and sustainable solutions that improve health and wellbeing, reduce cardiometabolic risk, and protect organs in people living with weight-related diseases. AstraZeneca has a strong heritage and experience in CVRM disease. We have one of the broadest and deepest pipelines in the industry. This uniquely positions us to improve outcomes for people affected by obesity, overweight, and diabetes in the future. We are developing oral and injectable therapies, using different modalities and novel mechanisms to expand access and tailor treatment strategies. Obesity and weight-related diseases are an emerging and priority area for AstraZeneca, where there is growing scientific interest and opportunities to transform outcome for those living with disease. It is an area where AstraZeneca has ambitions to be a leading company by delivering the next wave of life-changing medicines.
When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life‑changing medicines. In‑person working gives us the platform we need to connect, work at pace and challenge perceptions. That's why we work, on average, a minimum of three days per